‘Scientific gold rush’ created by quest for universal immunotherapy

cancer immunotherapy birak
Image credit: CBC

The drug industry has made a mint on immunotherapies for cancer, but those game-changing treatments don’t work for most people’s tumors. That has set in motion a scientific gold rush, as biotech companies search for molecules they can add to those drugs to turn them into universal therapies.

The latest promising candidate is TGF-beta, a thorny collection of proteins that regulates a host of bodily functions. Among them is the process by which the immune system decides to either attack cancerous growths or let them pass idly by.

Early data suggest that adding a drug that blocks TGF-beta to blockbuster cancer treatments like Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo could help vanquish tumors.

[R]esearchers have learned the hard way that making products out of a winning idea is more complicated than simply cooking up a targeted drug. TGF-beta is not a discrete target but rather what scientists call a superfamily.

Related article:  Could a virus be causing mysterious ‘polio-like’ disease affecting children?

Choose too few targets and your drug is likely to have no effect, but target TGF-beta indiscriminately and you risk attacking innocent proteins and running into damning toxicities, said John Quisel, [chief business officer at Acceleron Pharma].

“Our approach is that you have to have what I’ll call leavened activity against the right group of targets in order to find a balance on that spectrum between safety and activity,” Quisel said.

[Editor’s note: Full text is behind paywall]

Read full, original post: Biopharma has a new big idea for making cancer immunotherapy work better

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Video: Test everyone – Slovakia goes its own way to control COVID

Video: Test everyone – Slovakia goes its own way to control COVID

As Europe sees record coronavirus cases and deaths, Slovakia is testing its entire adult population. WSJ's Drew Hinshaw explains how ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend